The cohort comprised 358 treatment-naïve adults who initiated ABT-based therapy after being found to have baseline HIV-1 RNA above 500,000 copies per milliliter and CD4+ T-cell counts below 200 cells per microliter. Of these, 287 had an evaluable Week-12 virologic assessment, and this evaluable group formed the basis of the primary descriptive analysis. The starting point was severe: the median baseline viral load was 1,060,000 copies per milliliter, with an interquartile range of 696,000 to 2,205,000 copies per milliliter, and the median CD4+ T-cell count was just 48 cells per microliter.

Within the evaluable group, 132 participants, or 46.0 percent, were classified as CDC stage C3, reflecting advanced immunosuppression. The primary endpoint was the proportion of patients achieving virologic suppression at Week 12. Among the 287 participants with evaluable Week-12 results, 40.4 percent, or 116 individuals, reached HIV-1 RNA below 50 copies per milliliter, and 76.3 percent, or 219 individuals, reached below 200 copies per milliliter.

The magnitude of viral decline was substantial: the median change from baseline in HIV-1 RNA was minus 4.3 log10 copies per milliliter over the 12-week period. Alongside the virologic response, CD4+ T-cell counts increased over the 12 weeks, with a mean rise of 122.5 cells per microliter among the Week-12 evaluable participants, indicating concurrent immune recovery during early treatment. Because retrospective cohorts inevitably lose patients to follow-up, the researchers also performed a conservative sensitivity analysis using non-responder imputation across all 358 treatment initiators.

Under this approach, every participant without an evaluable Week-12 viral-load measurement was classified as a non-responder. The resulting suppression rates were 32.4 percent for HIV-1 RNA below 50 copies per milliliter and 61.2 percent for below 200 copies per milliliter. Safety findings over the 12-week observation period were favorable in this severely ill group.

Among the 287 participants included in the 12-week safety analysis, 45 individuals, or 15.7 percent, had at least one recorded Grade 1 or Grade 2 laboratory abnormality. No Grade 3 laboratory abnormalities, serious adverse events, adverse event-related treatment discontinuations or regimen switches, or deaths were recorded during the observation window. For a cohort in which the median CD4+ count at baseline was 48 cells per microliter and the median viral load exceeded one million copies per milliliter, the absence of recorded serious adverse events and treatment interruptions is a notable descriptive observation, though the retrospective design limits how systematically adverse events were captured.

The study's design shapes what its results can and cannot show. As a retrospective, single-arm cohort without a comparator regimen, it documents associations between ABT-based therapy and early outcomes rather than demonstrating comparative efficacy. The authors state explicitly that these observational findings warrant further evaluation in prospective comparative studies before any stronger conclusions can be drawn about how ABT-based regimens perform relative to alternatives in this population.

The distinction between the two analytical frames is central to reading the results correctly. The evaluable-cohort figures of 40.4 percent below 50 copies per milliliter and 76.3 percent below 200 copies per milliliter describe outcomes only among patients who remained in follow-up with a valid Week-12 measurement. The non-responder imputation figures of 32.4 percent and 61.2 percent across all 358 initiators answer a different question: what proportion of everyone who started therapy achieved suppression, counting missing outcomes as failures.

Both perspectives are reported in the study, and the gap between them, roughly eight percentage points at the stricter threshold and fifteen at the looser one, illustrates how much missing data can shift apparent success rates in real-world cohorts of critically ill patients. The reported pattern of a median 4.3 log10 reduction in HIV-1 RNA, rising CD4+ T-cell counts, and no recorded Grade 3 laboratory abnormalities, serious adverse events, or deaths over 12 weeks describes what was observed in this cohort under routine clinical conditions. Whether these early results translate into durable suppression and superior outcomes compared with other regimen choices will require the prospective, comparative studies the authors call for, since the present analysis was not designed to establish causal effects or relative efficacy.

Subject of Research: Early virologic and immunologic outcomes of albuvirtide-based antiretroviral regimens in treatment-naïve adults with advanced HIV disease and ultra-high viral loads

Article Title: Early virologic and immunologic outcomes of albuvirtide-based regimens in treatment-naïve adults with advanced HIV disease and ultra-high viral loads: a multicenter retrospective cohort study

Article References: Yuan, J., Deng, Y., Wang, J., Fu, Y., Guan, Y., Liu, K., Tian, B., Cai, L., Jiao, M., Hong, K., Huang, Z., Liu, C., Yan, Y., Zhang, Y., Li, S., Xia, Z., Jian, A., Yan, J., Shi, L., … Liu, M. (2026). Early virologic and immunologic outcomes of albuvirtide-based regimens in treatment-naïve adults with advanced HIV disease and ultra-high viral loads: a multicenter retrospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14647-y

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14647-y

Keywords: HIV-1, albuvirtide, antiretroviral therapy, viral load, CD4+ T-cell count, advanced HIV disease, retrospective cohort study, virologic suppression, treatment-naïve adults, China, BMC Infectious Diseases, Early